Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD(TM) Nano-Optic Lens Technology

Executive Summary

• Rise Nano Optics’ SPECTRAGUARD™ nano‑optic lens technology received FDA registration and was classified as a Class I exempt medical device.
• The FDA accepted the company’s intended‑use claim, allowing importation of the product into the United States and full launch of U.S. commercialization efforts.
• The milestone de‑risks the business and supports the company’s multi‑channel go‑to‑market strategy targeting eye‑care professionals, lens manufacturers, optical labs, eyewear brands, and direct‑to‑consumer platforms in a $160 billion global eyewear market.

Key Details

• FDA Classification: Class I exempt medical device (no pre‑market approval required).
• Intended Use Claim Accepted: Provides eye protection by filtering 100 % UV light and up to 90 % of wavelengths between 400–600 nm (including blue light) while preserving visual clarity and color perception.
• Commercial Impact: Enables importation and full U.S. market launch; the United States represents a major revenue opportunity within the global eyewear market.
• Leadership Update: Erik Ritchie appointed Chief Commercial Officer to drive U.S. commercialization.
• Target Markets: Eye‑care professionals, lens manufacturers, optical labs, eyewear brands, direct‑to‑consumer platforms.
• Market Context: Over 90 % of U.S. adults wear some form of eyewear; the addressable market includes users affected by screen exposure, light sensitivity, and degenerative eye conditions.
• Technology Highlights: Proprietary nano‑particle lens architecture selectively filters high‑energy visible light (400–600 nm) while maintaining natural color accuracy and visual clarity; designed to reduce glare, digital eye strain, and long‑term vision stress.
• Intellectual Property: Multiple patents covering nano‑material formulations, lens architecture, and scalable manufacturing processes.
• Regulatory Milestone Significance: Described by the CEO as an “important de‑risking event” that validates safety profile and supports accelerated commercialization across North America.

Notable Quotes

“FDA registration and Class I classification validate the safety profile and intended use of our SPECTRAGUARD™ technology and allow us to continue executing our multi‑pronged commercialization strategy… I am very proud of this accomplishment for the Company.” – Inas Said, Founder & CEO, Rise Nano Optics Ltd.